- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03208998
The Changes of Natural Killer Cells Frequency and Function During Antiviral Therapy
July 10, 2017 updated by: Yao Xie, Beijing Ditan Hospital
The Changes of Natural Killer Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B.
Pegylated interferon α-2a(Peg-IFN-α) not only inhibit viral replication, but also play an important role in immune regulation, while Nucleoside analog(ue) drugs only inhibit viral replication.
In hepatitis B infection, NKs are the main effector cells in early antiviral innate immune response.
This study was aimed at investigating the changes of NKs frequency and function, and the expression of costimulatory molecules during Peg-IFN-αand nucleoside analog(ue) therapy.Meanwhile, investigators want to verify whether Peg IFN - alpha suppressed the virus and the reduction of virus led to the recovery of NKs function, or Peg IFN - alpha enhanced NKs function which gave rise to the decline of the virus.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Pegylated interferon α-2a(Peg-IFN-α)and Nucleoside analog(ue) drugs can inhibit viral replication , but Peg-IFN-α also play an important role in immune regulation .
In hepatitis B infection, NKs are the main effector cells in early antiviral innate immune response.Peg-IFN-α recommended as the first-line treatment has a higher chance to achieve HBeAg seroconversion and even HBsAg disappearance than nucleoside analog(ue) drugs, which may be related to the functional activation of pDCs in the case of hepatitis and the function enhancement of NKs during Peg-IFN-α therapy.
This study was aimed at investigating the changes of NKs frequency and function, and the expression of costimulatory molecules during Peg-IFN-αand nucleoside analog(ue) therapy.Meanwhile, investigators want to explore whether the decline of HBsAg and HBeAg resulted in recovery of NKs function, or recovery of NKs function led to the decrease of HBsAg and HBeAg.
Several studies demonstrated that HBsAg and HBeAg could damage NKs function, and the loss of HBsAg and HBeAg led to recovery of NKs function.
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100015
- Recruiting
- Beijing Ditan Hospital,Capital Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 60 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- HBsAg and HBeAg positive for more than 6 months, HBV DNA detectable with ALT level abnormal lasted for three months and at least time190 IU/L or liver puncture biopsy demonstrated apparent inflammation, never treated before enrolled.
Exclusion Criteria:
- Active consumption of alcohol and/or drugs
- Co-infection with human immunodeficiency virus, hepatitis C virus, or hepatitis D virus
- History of autoimmune hepatitis
- Psychiatric disease
- Evidence of neoplastic diseases of the liver
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: experimental group
patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
|
patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
Other Names:
|
NO_INTERVENTION: control group
patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the changes of Natural Killer Cells
Time Frame: at baseline and at treatment week 12, 24
|
the changes of NK%,CD56bri/NK%,CD56dim/NK%,IFNAR2+NK%,IFNAR2MFI,NKp46+/NK%,NKp46dim/NK%,NKp46high/NK%, NKp46MFI,and NKp46ABC will be measured by flow cytometry during Pegylated Interferon α-2a and Nucleoside Analogues Treatment
|
at baseline and at treatment week 12, 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the change of HBVDNA levels (IU/ML)
Time Frame: at baseline and at treatment 12, 24, 36, 48 weeks
|
the curative effect of antiviral therapy will be evaluated by HBV markers and HBV DNA levels and liver function
|
at baseline and at treatment 12, 24, 36, 48 weeks
|
the change of ALT levels(U/L)
Time Frame: at baseline and at treatment 12, 24, 36, 48 weeks
|
the curative effect of antiviral therapy will be evaluated by HBV markers and HBV DNA levels and liver function
|
at baseline and at treatment 12, 24, 36, 48 weeks
|
the change of AST levels(U/L)
Time Frame: at baseline and at treatment 12, 24, 36, 48 weeks
|
the curative effect of antiviral therapy will be evaluated by HBV markers and HBV DNA levels and liver function
|
at baseline and at treatment 12, 24, 36, 48 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2016
Primary Completion (ANTICIPATED)
December 1, 2017
Study Completion (ANTICIPATED)
December 1, 2017
Study Registration Dates
First Submitted
June 30, 2017
First Submitted That Met QC Criteria
July 3, 2017
First Posted (ACTUAL)
July 6, 2017
Study Record Updates
Last Update Posted (ACTUAL)
July 12, 2017
Last Update Submitted That Met QC Criteria
July 10, 2017
Last Verified
July 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis B
- Hepatitis
- Hepatitis A
- Hepatitis B, Chronic
- Hepatitis, Chronic
- Anti-Infective Agents
- Antiviral Agents
- Peginterferon alfa-2a
Other Study ID Numbers
- DTXY012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Hepatitis B Infection
-
Brii Biosciences LimitedVir Biotechnology, Inc.Active, not recruitingChronic Hepatitis B Virus InfectionSingapore, Thailand, Australia, China, Korea, Republic of
-
Yangshengtang Co., LtdNot yet recruitingChronic Hepatitis B Virus Infection
-
Enanta Pharmaceuticals, IncTerminatedChronic Hepatitis B Virus InfectionNew Zealand
-
Enanta Pharmaceuticals, IncPharmaceutical Research AssociatesCompletedChronic HBV InfectionUnited States, Canada
-
Bristol-Myers SquibbCompletedChronic Hepatitis C Virus Infection | Chronic Hepatitis B Virus InfectionUnited States
-
Beijing Ditan HospitalUnknownChronic Hepatitis B InfectionChina
-
Sun Yat-sen UniversityRecruitingChronic Hepatitis B Virus InfectionChina
-
PharmaEssentiaRecruitingChronic Hepatitis B Infection | Chronic Hepatitis D InfectionTaiwan
-
Hoffmann-La RocheTerminatedHepatitis B Virus InfectionUnited Kingdom, Hong Kong, Korea, Republic of, Taiwan, Poland, Bulgaria, New Zealand
-
French National Agency for Research on AIDS and...Gilead Sciences; PharmassetTerminatedHBe Negative Chronic Hepatitis B | Hepatitis B Viral InfectionFrance
Clinical Trials on Peginterferon Alfa-2a
-
Third Affiliated Hospital, Sun Yat-Sen UniversityPeking University; Huazhong University of Science and Technology; First People... and other collaboratorsUnknown
-
Third Affiliated Hospital, Sun Yat-Sen UniversityPeking University; Huazhong University of Science and Technology; First People... and other collaboratorsUnknownChronic Hepatitis BChina
-
Hoffmann-La RocheCompleted
-
Xiamen Amoytop Biotech Co., Ltd.Peking University First HospitalCompleted
-
The Second Affiliated Hospital of Chongqing Medical...Unknown
-
Hoffmann-La RocheCompletedHepatitis B, ChronicRussian Federation
-
Hoffmann-La RocheCompletedHepatitis B, ChronicTaiwan, United States, New Zealand, Singapore
-
Hoffmann-La RocheCompletedHepatitis C, ChronicRussian Federation
-
Chugai PharmaceuticalCompleted
-
Hoffmann-La RocheCompletedHepatitis C, ChronicBelgium, Ireland, Italy, United Kingdom